

Primary Hyperparathyroidism Committee meeting 2

Date: 11/09/2017

Location: NGC Boardroom

Minutes: Confirmed

Committee members present:		
Jonathan Mant (Chair) (JM)		(Present for notes 1 – 5)
Neil Gittoes (NG)		(Present for notes 1 – 5)
Terry Aspray (TA)		(Present for notes 1 – 5)
Julie Cox (JC)		(Present for notes 1 – 5)
Joy Foster (JF)		(Present for notes 1 – 5)
Fausto Palazzo (FP)		(Present for notes 1 – 5)
Peter Selby (PS)		(Present for notes 1 – 5)
Anthony Skene (AS)		(Present for notes 1 – 5)
Nicholas Thomson (NT)		(Present for notes 1 – 5)

In attendance:		
Margaret Constanti (MC)	Senior Health Economist, NGC	(Present for notes 1 – 5)
Andrew Harding (AH)	Guidelines Commissioning Manager, NICE	(Present for notes 1 – 5)
Samantha Jones (SJ)	Project Manager, NGC	(Present for notes 1 – 5)
Emily Terrazas-Cruz (ETC)	Senior Research Fellow, NGC	(Present for notes 1 – 5)

Observers:		
Tracey Moore (TM)	Chair, Tinnitus Guideline Committee	(Present for notes 1 – 5)

Apologies:		
Terry Aspray (TA)	Guideline Committee	
Katie Broomfield (KB)	Document Editor/Process Assistant, NGC	

Jill Cobb (JCo)	Information Specialist, NGC
Parijat De (PD)	Guideline Committee
Imran Jawaid (IJ)	Guideline Committee
Jane Lynn (JL)	Business Analyst, NICE
Sharangini Rajesh (SR)	Research Fellow, NGC
Sharon Swain (SS)	Operations Director/Guideline lead, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the second meeting on primary hyperparathyroidism. The Committee members and attendees introduced themselves.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting.

Introductions

2. Confirmation of matter under discussion, and declarations of interest

The Chair asked everyone to verbally declare any interests that have arisen since application. The following new interests were received for this committee meeting:

Committee Declarations of Interest			
N.B. The Chair and Committee members were recruited to this guideline using NICE DOI policy published Sept 2014.			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
AS	Undertakes private practice.	Personal financial specific	Declare and participate
NICE DOI policy classifications are: <ul style="list-style-type: none"> • Personal financial specific • Personal financial non-specific • Personal non-financial specific • Personal non-financial non-specific • Non-personal financial specific • Non-personal financial non-specific 			

The DOI register was made available to the Committee chair. The chair reviewed the DOI register and deemed that none of the original DOIs were in conflict with the agenda topics and clinical questions under discussion at the meeting.

3. Minutes of the last meeting

The committee reviewed the minutes from the last meeting and agreed that they were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Presentations and discussion

3.1 ETC presented the clinical evidence for the calcimimetics evidence review. MC presented the health economic considerations. The GC discussed the evidence.

3.2 MC led a discussion to determine health economic modelling priorities for the guideline.

3.3 ETC led a discussion on the draft protocol for diagnostic tests.

5. Any other business

The group discussed next steps and agreed action points.

Date of next meeting: 02/11/2017

Location of next meeting: Boardroom, National Guideline Centre, 180 Great Portland Street, London, W1W 5QZ